Quick Answer
Hepion Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2023.
Hepion Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue (ASC 606) | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.28M +37.3% |
-$13.19M +73.0% |
-$48.93M -15.9% |
-$42.20M -29.0% |
-$32.72M -60.8% |
-$20.35M -189.2% |
| Diluted EPS | -$0.88 +99.2% |
-$107.35 +82.6% |
-$616.07 -5077.1% |
-$11.90 -2431.9% |
-$0.47 +77.6% |
-$2.10 |
| Total Assets | $3.07M +90.2% |
$1.61M -91.1% |
$18.09M -70.0% |
$60.24M -41.8% |
$103.55M +112.9% |
$48.65M +136.0% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | $2.67M +243.2% |
-$1.86M -125.6% |
$7.28M -85.4% |
$49.86M -57.6% |
$117.58M +190.2% |
$40.52M +159.5% |
| R&D Expense | $445.5K -96.2% |
$11.85M -66.8% |
$35.64M +7.1% |
$33.27M +63.1% |
$20.40M +70.0% |
$12.00M +276.8% |
| Operating Income | -$4.16M +78.5% |
-$19.35M +60.1% |
-$48.45M -6.5% |
-$45.49M -49.6% |
-$30.40M -50.9% |
-$20.15M -159.3% |
| Shares Outstanding | 11.62M +8249.8% |
139,168 +44.4% |
96,375 -97.5% |
3.81M -95.0% |
76.23M +138.0% |
32.03M +751.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | March 31, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$472.5K | +90.3% | +54.7% |
| Diluted EPS | September 30, 2025 | -$0.04 | +99.9% | +55.6% |
| Total Assets | September 30, 2025 | $3.74M | +0.7% | -17.0% |
| Cash and Equivalents | September 30, 2019 | $14.86M | +64.6% | -13.3% |
| Stockholders Equity | September 30, 2025 | $3.32M | +717.4% | -12.4% |
| R&D Expense | June 30, 2025 | $423.3K | -94.1% | +1803.7% |
| Operating Income | September 30, 2025 | -$527.9K | +88.2% | +69.8% |
| Shares Outstanding | September 30, 2025 | 11.62M | +67.0% | +0.0% |
- Hepion Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2023.
- Hepion Pharmaceuticals, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2023.
- Hepion Pharmaceuticals, Inc. reported Net Income of -$8.28 million for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +37.3% in Net Income compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Diluted EPS of $0.88 per share (loss) for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +99.2% in Diluted EPS compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Total Assets of $3.07 million for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +90.2% in Total Assets compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Cash and Equivalents of $13.92 million for fiscal year 2019.
- Hepion Pharmaceuticals, Inc. showed an increase of +391.6% in Cash and Equivalents compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Stockholders Equity of $2.67 million for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +243.2% in Stockholders Equity compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported R&D Expense of $445.5 thousand for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed a decrease of -96.2% in R&D Expense compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Operating Income of -$4.16 million for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +78.5% in Operating Income compared to the prior fiscal year.
- Hepion Pharmaceuticals, Inc. reported Shares Outstanding of 11.62 million shares for fiscal year 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +8249.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: